Literature DB >> 25127482

Combining incretin-based drugs and RAAS inhibitors: more cons than pros?

Lennart Tonneijck1, Marcel H A Muskiet2, Mark M Smits2, Daniël H van Raalte2, Michaela Diamant2.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25127482     DOI： 10.1016/S2213-8587(14)70167-6

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  3 in total

Review 1.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.

Authors:  Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles
Journal:  J Am Soc Nephrol       Date:  2017-01-31       Impact factor: 10.121

2.  Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.

Authors:  Mark M Smits; Marcel H A Muskiet; Lennart Tonneijck; Trynke Hoekstra; Mark H H Kramer; Michaela Diamant; Daniël H van Raalte
Journal:  Br J Clin Pharmacol       Date:  2016-01-25       Impact factor: 4.335

3.  Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.

Authors:  Marcel H A Muskiet; Lennart Tonneijck; Mark M Smits; Mark H H Kramer; D Margriet Ouwens; Bolette Hartmann; Jens J Holst; A H Jan Danser; Jaap A Joles; Daniël H van Raalte
Journal:  Diabetes Obes Metab       Date:  2021-10-06       Impact factor: 6.408
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.